{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:48:51Z","timestamp":1793216931374,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neoantigen vaccines and oncolytic viruses are emerging immunotherapies that can reshape the tumor microenvironment (TME). However, tumors with low mutation burdens often respond poorly to immunotherapies because of their limited immunogenicity. Developing effective immunotherapy strategies for these types of tumors remains a significant challenge. In this study, we engineered oncolytic adenoviruses to accurately amplify neoantigen expression within tumor cells, which demonstrated superior efficacy compared to synthetic long peptide vaccines and showed enhanced effectiveness in a low mutation burden intrahepatic cholangiocarcinoma model. Building on this, we further developed NeoViron, which coexpresses neoantigens and Flt3L, a dendritic cell growth factor, to promote antigen presentation and T-cell infiltration simultaneously. NeoViron significantly inhibited tumor growth and prevented metastasis in intrahepatic cholangiocarcinoma animal models. Mechanistically, NeoViron enhanced the cytotoxicity of CD8+\u2009T cells and promoted the expansion of CD69+\u2009CD8+ tissue-resident memory T cells and TCF1+\u2009CD8+ stem-like T cells to promote anti-tumor immunity and immune memory. When combined with anti-PD-1, it further enhances the cytotoxicity of tissue-resident memory T cells to eradicate solid tumors. These findings demonstrate that NeoViron can effectively sensitize low-mutation tumors to immunotherapy by increasing neoantigen expression and antigen-presentation efficacy, offering a promising strategy for cancer treatment, particularly for tumors with scarce neoantigens.<\/jats:p>","DOI":"10.1038\/s41392-025-02511-5","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:01:54Z","timestamp":1766448114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis"],"prefix":"10.1038","volume":"10","author":[{"given":"Ke-Yu","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Zhe","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1141-0668","authenticated-orcid":false,"given":"Ying-Han","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Zhe","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SamI","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Tian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-7248","authenticated-orcid":false,"given":"Chang-Qing","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lun-Xiu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"2511_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","volume":"17","author":"K-Y Shen","year":"2024","unstructured":"Shen, K.-Y., Zhu, Y., Xie, S.-Z. & Qin, L.-X. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J. Hematol. Oncol. 17, 25 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2511_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis, P. D., Ishii, K. J. & Schliehe, C. Challenges in developing personalized neoantigen cancer vaccines. Nat. Rev. Immunol. 24, 213\u2013227 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2511_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"2511_CR4","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","volume":"40","author":"MM Awad","year":"2022","unstructured":"Awad, M. M. et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell 40, 1010\u20131026 (2022).","journal-title":"Cancer Cell"},{"key":"2511_CR5","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619\u20131629 (2022).","journal-title":"Nat. Med."},{"key":"2511_CR6","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha, D. et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 10, 1808\u20131825 (2020).","journal-title":"Cancer Discov."},{"key":"2511_CR7","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jhep.2020.11.037","volume":"74","author":"LP Diggs","year":"2021","unstructured":"Diggs, L. P. et al. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. J. Hepatol. 74, 1145\u20131154 (2021).","journal-title":"J. Hepatol."},{"key":"2511_CR8","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2511_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma, R. et al. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer 9, 122\u2013139 (2023).","journal-title":"Trends Cancer"},{"key":"2511_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","volume":"641","author":"Y Shen","year":"2025","unstructured":"Shen, Y. et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature 641, 503\u2013511 (2025).","journal-title":"Nature"},{"key":"2511_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","volume":"188","author":"L Zhong","year":"2025","unstructured":"Zhong, L. et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell 188, 1119\u20131136 (2025).","journal-title":"Cell"},{"key":"2511_CR12","doi-asserted-by":"crossref","unstructured":"Li, S. et al. Amplifying antigen-induced cellular responses with proximity labelling. Nature 647, 506\u2013516 (2025).","DOI":"10.1038\/s41586-025-09518-6"},{"key":"2511_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz1863","volume":"12","author":"AK Park","year":"2020","unstructured":"Park, A. K. et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci. Transl. Med. 12, eaaz1863 (2020).","journal-title":"Sci. Transl. Med."},{"key":"2511_CR14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-024-00760-x","volume":"5","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy. Nat. Cancer 5, 1063\u20131081 (2024).","journal-title":"Nat. Cancer"},{"key":"2511_CR15","doi-asserted-by":"publisher","first-page":"e004691","DOI":"10.1136\/jitc-2022-004691","volume":"10","author":"Y Su","year":"2022","unstructured":"Su, Y. et al. Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors. J. Immunother. Cancer 10, e004691 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2511_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","volume":"21","author":"J Lai","year":"2020","unstructured":"Lai, J. et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat. Immunol. 21, 914\u2013926 (2020).","journal-title":"Nat. Immunol."},{"key":"2511_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1053\/j.gastro.2022.05.007","volume":"163","author":"S Hu","year":"2022","unstructured":"Hu, S. et al. NOTCH-YAP1\/TEAD-DNMT1 axis drives hepatocyte reprogramming into intrahepatic cholangiocarcinoma. Gastroenterology 163, 449\u2013465 (2022).","journal-title":"Gastroenterology"},{"key":"2511_CR18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572\u2013576 (2014).","journal-title":"Nature"},{"key":"2511_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46367-9","volume":"15","author":"JP Finnigan","year":"2024","unstructured":"Finnigan, J. P. et al. Structural basis for self-discrimination by neoantigen-specific TCRs. Nat. Commun. 15, 2140 (2024).","journal-title":"Nat. Commun."},{"key":"2511_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn9083","volume":"386","author":"E Ascic","year":"2024","unstructured":"Ascic, E. et al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science 386, eadn9083 (2024).","journal-title":"Science"},{"key":"2511_CR21","doi-asserted-by":"publisher","first-page":"e004389","DOI":"10.1136\/jitc-2021-004389","volume":"10","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models. J. Immunother. Cancer 10, e004389 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2511_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41590-020-00810-3","volume":"22","author":"F Baharom","year":"2021","unstructured":"Baharom, F. et al. Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. Nat. Immunol. 22, 41\u201352 (2021).","journal-title":"Nat. Immunol."},{"key":"2511_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo7604","volume":"14","author":"AM D\u2019Alise","year":"2022","unstructured":"D\u2019Alise, A. M. et al. Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection. Sci. Transl. Med. 14, eabo7604 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2511_CR24","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1016\/j.cell.2021.08.020","volume":"184","author":"ML Burger","year":"2021","unstructured":"Burger, M. L. et al. Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell 184, 4996\u20135014 (2021).","journal-title":"Cell"},{"key":"2511_CR25","doi-asserted-by":"publisher","first-page":"e008739","DOI":"10.1136\/jitc-2023-008739","volume":"12","author":"SG De Le\u00f3n-Rodr\u00edguez","year":"2024","unstructured":"De Le\u00f3n-Rodr\u00edguez, S. G. et al. TCF1-positive and TCF1-negative TRM CD8 T cell subsets and cDC1s orchestrate melanoma protection and immunotherapy response. J. Immunother. Cancer 12, e008739 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2511_CR26","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013 (2018).","journal-title":"Cell"},{"key":"2511_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","volume":"56","author":"J Park","year":"2023","unstructured":"Park, J., Hsueh, P.-C., Li, Z. & Ho, P.-C. Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity. Immunity 56, 32\u201342 (2023).","journal-title":"Immunity"},{"key":"2511_CR28","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41577-024-01040-6","volume":"24","author":"N Lam","year":"2024","unstructured":"Lam, N., Lee, Y. & Farber, D. L. A guide to adaptive immune memory. Nat. Rev. Immunol. 24, 810\u2013829 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2511_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211 (2019).","journal-title":"Immunity"},{"key":"2511_CR30","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen, C. S. et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465\u2013470 (2019).","journal-title":"Nature"},{"key":"2511_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41590-023-01664-1","volume":"25","author":"LJ Stern","year":"2024","unstructured":"Stern, L. J., Clement, C., Galluzzi, L. & Santambrogio, L. Non-mutational neoantigens in disease. Nat. Immunol. 25, 29\u201340 (2024).","journal-title":"Nat. Immunol."},{"key":"2511_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn6056","volume":"14","author":"S Matsushima","year":"2022","unstructured":"Matsushima, S. et al. Chemical induction of splice-neoantigens attenuates tumor growth in a preclinical model of colorectal cancer. Sci. Transl. Med. 14, eabn6056 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2511_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.immuni.2024.12.004","volume":"58","author":"J Champagne","year":"2025","unstructured":"Champagne, J. et al. Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. Immunity 58, 247\u2013262 (2025).","journal-title":"Immunity"},{"key":"2511_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"520","author":"S Kreiter","year":"2015","unstructured":"Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692\u2013696 (2015).","journal-title":"Nature"},{"key":"2511_CR35","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701 (2019).","journal-title":"Nature"},{"key":"2511_CR36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41586-024-08033-4","volume":"635","author":"A Redenti","year":"2024","unstructured":"Redenti, A. et al. Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature 635, 453\u2013461 (2024).","journal-title":"Nature"},{"key":"2511_CR37","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888\u20131902 (2019).","journal-title":"Cell"},{"key":"2511_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-019-0969-x","volume":"566","author":"J Cao","year":"2019","unstructured":"Cao, J. et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature 566, 496\u2013502 (2019).","journal-title":"Nature"},{"key":"2511_CR39","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","volume":"20","author":"S Jin","year":"2025","unstructured":"Jin, S., Plikus, M. V. & Nie, Q. CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat. Protoc. 20, 180\u2013219 (2025).","journal-title":"Nat. Protoc."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02511-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02511-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02511-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:01:55Z","timestamp":1766448115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02511-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2511"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02511-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"410"}}